Intravenous administration of human umbilical cord blood-mononuclear cells dose-dependently relieve neurologic deficits in rat intracerebral hemorrhage model.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: G. Fischer Country of Publication: Germany NLM ID: 100963897 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-0402 (Electronic) Linking ISSN: 09409602 NLM ISO Abbreviation: Ann Anat Subsets: MEDLINE
    • Publication Information:
      Original Publication: Jena [Germany] ; New York : G. Fischer, c1992-
    • Subject Terms:
      Cord Blood Stem Cell Transplantation/*methods ; Intracranial Hemorrhages/*complications ; Intracranial Hemorrhages/*therapy ; Monocytes/*transplantation ; Nervous System Diseases/*etiology ; Nervous System Diseases/*prevention & control; Animals ; Antimetabolites ; Behavior, Animal/physiology ; Brain/pathology ; Bromodeoxyuridine ; Cell Movement ; Cell Separation ; Cell Survival ; Centrifugation, Density Gradient ; Flow Cytometry ; Humans ; Immunohistochemistry ; Intracranial Hemorrhages/pathology ; Leukocyte Common Antigens/metabolism ; Male ; Rats ; Rats, Wistar ; Recovery of Function ; Stroke/etiology ; Stroke/therapy
    • Abstract:
      Human umbilical cord blood (HUCB) is now considered as a valuable source for stem cell-based therapies. Previous studies showed that intravascular injection of the HUCB significantly improves neurological functional recovery in a model of intracerebral hemorrhage (ICH). To extend these findings, we examined the behavioral recovery and injured volume in the presence of increasing doses of human umbilical cord blood derived mononuclear cells (HUC-MCs) after intracerebral hemorrhage in rats. The experimental ICH was induced by intrastriatal administration of bacterial collagenase IV in adult rats. One day after the surgery, the rats were randomly divided into 4 groups to receive intravenously either BrdU positive human UC-MCs (4 × 10(6), 8 × 10(6) and 16 × 10(6) cells in 1 ml saline, n=10, respectively) as treated groups or the same amount of saline as lesion group (n=10). There was also one group (control n=10) that received only the vehicle solution of collagenase. The animals were evaluated for 14 days with modified limb placing and corner turn tests. The transplanted human UC-MCs were also detected by immunohistochemistry with labeling of BrdU. Two weeks after infusion, there was a significant recovery in the behavioral performance when 4 × 10(6) or more UC-MCs were delivered (P<0.05-0.001). Injured volume measurements disclosed an inverse relationship between UC-MCs dose and damage reaching significance at the higher UC-MCs doses. Moreover, human UC-MCs were localized by immunohistochemistry only in the injured area. Intravenously transplanted UC-MCs can accelerate the neurological function recovery of ICH rat and diminish the striatum lesion size by demonstrating a dose relationship between them.
      (Copyright © 2012 Elsevier GmbH. All rights reserved.)
    • Accession Number:
      0 (Antimetabolites)
      EC 3.1.3.48 (Leukocyte Common Antigens)
      G34N38R2N1 (Bromodeoxyuridine)
    • Publication Date:
      Date Created: 20120710 Date Completed: 20130711 Latest Revision: 20171116
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.aanat.2012.05.002
    • Accession Number:
      22770555